Identifying precisely how a biological or chemical entity interacts with the human cell is fundamental to furthering our understanding of both normal biological and disease processes as well as revealing the mechanism of action of drugs and their potential for toxicity. Retrogenix’s unique cell microarray technology provides a fast, accurate and effective solution for discovering the human cell surface and secreted protein targets of antibodies, proteins, viruses and small molecules. This allows our global pharmaceutical clients to:
Retrogenix’s biologically-relevant system detects specific interactions with a high degree of sensitivity. This unique tool uses proprietary arrays of expression vectors – encoding over 6,200 full-length human plasma membrane and tethered secreted proteins – spotted onto slides. Human cells grown over the top become reverse-transfected resulting in cell surface expression of each respective protein at distinct slide locations. The test molecule is applied and specific binding analysed and confirmed using an appropriate detection system.
The Retrogenix technology is compatible with a wide range of different ligands. We have successfully screened:
Antibodies and related molecules
mAbs, bispecifics, antibody-drug conjugates (ADCs), antibody fragments such as ScFvs, Fabs DARPins and mimetics, Fc-fusion proteins;
viruses, organelles and whole cells, including CAR T;
Proteins and peptides
directly fluorescently conjugated or tagged proteins (Fc-tagged, biotinylated, Flag-tagged, His-tagged), monomers, multimers, protein-specific secondaries, polyclonal antisera, purified and media supernatants.
Retrogenix has built a high quality library of plasma membrane and secreted proteins for screening ….
Our results have been used in many high impact peer-reviewed publications and multiple patent applications, and are regularly presented at international conferences. Our case studies highlight a selection of these projects providing further details on receptor identification, target deconvolution and specificity screening for biotherapeutics such as CAR T cells and antibodies.